Skip to main content

Table 2 Efficacy of PD-1/PD-L1 inhibitors

From: Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

  n = 19
median number of Cycle (range) 7 (1–70)
Duration of treatment 2.8 months (1 day-32.9 months)
Best response during administrationa PR 4, SD 12, PD 1, NE 2
Best response including after discontinuationa CR 1, PR 5, SD 11, PD 2
(PR → CR 1, SD → PR 2, NE → SD, PD1)
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated
  2. aAccording to RECIST 1.1; Confirmed by a later scan performed at least 4 weeks after initial response was observed